Doravirine/tenofovir disoproxyl fumarate/lamivudine-induced alopecia: A case report. (June 2022)

• Record Type: Journal Article
• Authors: Cattaneo, Dario; Riva, Agostino; Poloni, Andrea; Carrozzo, Giorgia; Gervasoni, Cristina
• Is Part Of: International journal of STD & AIDS. Volume 33:Number 7(2022)
• Page Start: 726
• Page End: 727
• Publication Date: 2022-06
• Subjects: ART (antiretroviral therapy) < other -- toxicity < other -- AIDS < viral disease; Sexually transmitted diseases -- Periodicals; AIDS (Disease) -- Periodicals; 616.951
• DOI: 10.1177/09564624221096299
• Languages: English
• ISSNs: 0956-4624

Abstract

We report here a case of alopecia probably caused by the fixed dose combination of doravirine/tenofovir disproxil fumarate/lamivudine (DOR/TDF/3TC) in a 46-year-old male living with HIV, previously treated with tenofovir disproxil fumarate and lamivudine-containing antiretroviral combinations. After having excluded other causes of hair loss such as sexually transmitted disease or drugs associated with alopecia, as well as poor immune-virologic conditions (i.e. low CD4 + cell count and/or high HIV viral load), a toxic effect of doravirine might be hypothesized. DOR/TDF/3TC was immediately stopped and rilpivirine plus tenofovir alafenamide fumarate/emtricitabine was started. Four weeks after changing the antiretroviral regimen, the patient reported signs of hypopigmented hair regrowth. The association between the episode of alopecia and DOR/TDF/3TC was scored as probable according to the Naranjo causality scale. We concluded that alopecia was probably related to DOR but whether it is self-limiting, cannot be predicted at this stage.